BG Medicine and FDA to Conduct Joint Biomarker Discovery Study
News Oct 26, 2005
BG Medicine has announced the submission of a Cooperative Research and Development Agreement (CRADA) with the Food and Drug Administration's National Center for Toxicological Research (NCTR), to jointly conduct a liver toxicity study designed to overcome one of the primary obstacles to the efficient development of safe and effective drugs.
The study, Liver Toxicology Biomarker Study (LTBS), aims to discover biomarkers of human hepatotoxicity in the standard test used by pharmaceutical manufacturers in the initial stages of drug development.
The toxicity tests currently in use by drug companies have been unchanged for at least 40 years and often fail to identify human liver toxicity issues.
On March 16, 2004 the FDA released a report, “Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products,” describing the “urgent need to modernize the medical product development process - the Critical Path - to make product development more predictable and less costly.”
The proposed project addresses the liver toxicity issue highlighted in the Critical Path document as one of the obvious and priority areas for innovation.
The CRADA process is a standard procedure for studies the FDA undertakes in collaboration with private companies.
The liver toxicity study has been designed by BG Medicine and the FDA with input from a number of pharmaceutical companies.
The research project leverages NCTR's and BGM's systems biology platforms for functional genomics, proteomics, metabolomics and computational analysis.
The LTBS will be conducted at the FDA's NCTR laboratory in Jefferson, Arkansas and at BG Medicine in Waltham, Massachusetts.
The study is open to participation by all pharmaceutical manufacturers. Participating companies will receive a paid-up perpetual license to any biomarkers discovered and access to all project data.
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
Bird and Turtle Chromosomes Help Identify Dinosaur DNANews
Researchers have used bird and turtle DNA to extrapolate the chromosome structure of their common ancestor that lived around 260 million years ago – 20 million years before the dinosaurs first emerged. They were then able to trace the evolution of avian and non-avian dinosaur DNA through to the present day.
Over 130 Glaucoma Gene Variants Could Help Predict BlindnessNews
An international study has identified 133 genetic variants that could help predict the risk of developing glaucoma, the world’s leading cause of incurable blindness. The findings are an advance in the fight to tackle the incurable, degenerative condition, which has virtually no symptoms in the early stages, and could lead to a genetic-based screening program.READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018